The BRECISE project is a pioneering initiative that unites 25 leading partners from academic institutions, hospitals, industry, technology innovators, regulatory bodies, and patient organizations. This multidisciplinary collaboration is essential for accelerating biomarker-driven precision medicine solutions for prostate and bladder cancer.

Each partner plays a unique role in the development, validation, and implementation of biomarkers, ensuring scientific excellence, regulatory compliance, and patient-centered research.